(NASDAQ: QTTB) Q32 Bio's forecast annual revenue growth rate of 554.59% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.36%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.64%.
Q32 Bio's revenue in 2024 is $354,000.On average, 2 Wall Street analysts forecast QTTB's revenue for 2028 to be $1,033,889,818, with the lowest QTTB revenue forecast at $490,224,395, and the highest QTTB revenue forecast at $1,577,555,241. On average, 2 Wall Street analysts forecast QTTB's revenue for 2029 to be $3,409,418,119, with the lowest QTTB revenue forecast at $2,377,558,463, and the highest QTTB revenue forecast at $4,441,277,775.
In 2030, QTTB is forecast to generate $6,139,747,072 in revenue, with the lowest revenue forecast at $5,104,663,041 and the highest revenue forecast at $7,174,831,103.